Stock Research for RDHL

RDHL

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

RDHL Stock Chart & Research Data

The RDHL chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the RDHL chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


RDHL Due diligence Resources & Stock Charts

The RDHL stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View RDHL Detailed Price Forecast - CNN Money CNN View RDHL Detailed Summary - Google Finance
Yahoo View RDHL Detailed Summary - Yahoo! Finance Zacks View RDHL Stock Research & Analysis - Zacks.com

Stock Analysis

TradeIdeas View RDHL Trends & Analysis - Trade-Ideas Barrons View RDHL Major Holders - Barrons
NASDAQ View RDHL Call Transcripts - NASDAQ Seeking View RDHL Breaking News & Analysis - Seeking Alpha
Spotlight View RDHL Annual Report - CompanySpotlight.com OTC Report View RDHL OTC Short Report - OTCShortReport.com
TradeKing View RDHL Fundamentals - TradeKing Charts View RDHL SEC Filings - Bar Chart
WSJ View Historical Prices for RDHL - The WSJ Morningstar View Performance/Total Return for RDHL - Morningstar
MarketWatch View the Analyst Estimates for RDHL - MarketWatch CNBC View the Earnings History for RDHL - CNBC
StockMarketWatch View the RDHL Earnings - StockMarketWatch MacroAxis View RDHL Buy or Sell Recommendations - MacroAxis
Bullish View the RDHL Bullish Patterns - American Bulls Short Pains View RDHL Short Pain Metrics - ShortPainBot.com

Social Media Mentions

StockTwits View RDHL Stock Mentions - StockTwits PennyStocks View RDHL Stock Mentions - PennyStockTweets
Twitter View RDHL Stock Mentions - Twitter Invest Hub View RDHL Investment Forum News - Investor Hub
Yahoo View RDHL Stock Mentions - Yahoo! Message Board Seeking Alpha View RDHL Stock Mentions - Seeking Alpha


Financial & Transaction Holdings

SECform4 View Insider Transactions for RDHL - SECform4.com Insider Cow View Insider Transactions for RDHL - Insider Cow
CNBC View RDHL Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for RDHL - OTC Markets
Yahoo View Insider Transactions for RDHL - Yahoo! Finance NASDAQ View Institutional Holdings for RDHL - NASDAQ


Stock Charts

FinViz View RDHL Stock Insight & Charts - FinViz.com StockCharts View RDHL Investment Charts - StockCharts.com
BarChart View RDHL Stock Overview & Charts - BarChart Trading View View RDHL User Generated Charts - Trading View




Latest Financial News for RDHL


RedHill Biopharma to Present at Ladenburg Thalmann 2018 Healthcare Conference
Posted on Thursday September 20, 2018

TEL-AVIV, Israel and RALEIGH, N.C., Sept. 20, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on proprietary drugs for gastrointestinal diseases, today announced that Mr. Dror Ben-Asher, chief executive officer of RedHill, will present a corporate overview at the Ladenburg Thalmann 2018 Healthcare Conference, on Tuesday, Oct. 2, 2018, at 10:30 a.m. ET, at the Sofitel Hotel in New York City.


RedHill Biopharma Announces Positive End-of-Phase II Meeting with FDA on BEKINDA® for IBS-D
Posted on Wednesday September 12, 2018

The positive Type B meeting with the FDA followed a successful Phase II study of BEKINDA ® for diarrhea-predominant irritable bowel syndrome, one of the most common gastrointestinal disorders In light ...


RedHill Biopharma Announces Advancement to Second Stage of Phase IIa Study with YELIVA® for Cholangiocarcinoma
Posted on Thursday September 06, 2018

TEL-AVIV, Israel and RALEIGH, N.C., Sept. 06, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on proprietary drugs for gastrointestinal diseases, today announced that the ongoing single-arm Phase IIa study with orally-administered YELIVA® (opaganib, ABC294640)1 for the treatment of advanced cholangiocarcinoma (bile duct cancer) has achieved its pre-specified efficacy goal for the first stage of the two-stage study design, and as a result, the study will continue to its second stage, enrolling the full cohort of 39 evaluable patients. The primary efficacy endpoint of the study is defined as either partial or complete response, or stable disease at four months treatment with YELIVA®.


RedHill Biopharma Announces Completion of Enrollment for Confirmatory Phase III Study with TALICIA® for H. pylori Infection
Posted on Tuesday September 04, 2018

Top-line results from the randomized, double-blind confirmatory Phase III study with TALICIA ® are expected before year’ s end The ERADICATE Hp2 study enrolled 455 patients with confirmed H. pylori infection ...


Stock Market & Investing Books

Enter a stock symbol to view the stock details.